

Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Date: October 29, 2001

By:

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: 919-483-6983  
Fax: 919-483-5730